Schimke immunoosseous dysplasia and management considerations for vascular risks.


Journal

American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741

Informations de publication

Date de publication:
07 2019
Historique:
received: 28 09 2018
revised: 31 01 2019
accepted: 22 02 2019
pubmed: 1 5 2019
medline: 9 6 2020
entrez: 1 5 2019
Statut: ppublish

Résumé

Schimke immunoosseous dysplasia (SIOD) is a multisystemic condition characterized by early arteriosclerosis and progressive renal insufficiency, among other features. Many SIOD patients have severe, migraine-like headaches, transient neurologic attacks, or cerebral ischemic events. Cerebral events could be exacerbated or precipitated by hypertension, and it is unclear how these are related to arteriosclerotic changes as dyslipidemia is also a feature of SIOD. The correlation between hypercholesterolemia and cardiovascular risk in SIOD is unclear. Also, the etiology and management of headaches is not well characterized. Here we report our clinical observations in the management of SIOD in a patient who was diagnosed in school age despite early signs and symptoms. We describe biallelic variants, including a previously unreported c.1931G>A (p.Arg644Gln) variant in SMARCAL1. We specifically investigated whether migraine-like headaches and progressive nephropathy may be related to blood pressure dysregulation. We found a correlation between tighter blood pressure regulation using ambulatory blood pressure monitoring and a subjective decrease in headache symptoms. We discuss blood pressure medication management in SIOD. We also characterize dyslipidemia relative to atherosclerosis risks and provide new management strategies to consider for optimizing care.

Identifiants

pubmed: 31039288
doi: 10.1002/ajmg.a.61148
doi:

Substances chimiques

Anticholesteremic Agents 0
Antihypertensive Agents 0
Benzazepines 0
Propranolol 9Y8NXQ24VQ
Atorvastatin A0JWA85V8F
SMARCAL1 protein, human EC 2.7.7.-
DNA Helicases EC 3.6.4.-
benazepril UDM7Q7QWP8

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1246-1252

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Daniah T Beleford (DT)

Division of Medical Genetics, Department of Pediatrics, Institute for Human Genetics, University of California San Francisco, San Francisco, California.

Mohammad Diab (M)

Pediatric Orthopaedics, Department of Orthopaedic Surgery, University of California San Francisco, San Francisco, California.

William F Qubty (WF)

Pediatric Headache, Division of Child Neurology, Department of Neurology, University of California San Francisco, San Francisco, California.

Mary J Malloy (MJ)

Departments of Medicine and Pediatrics, Cardiovascular Research Institute, University of California San Francisco, San Francisco, California.

Roger K Long (RK)

Division of Pediatric Endocrinology, Department of Pediatrics, University of California San Francisco, San Francisco, California.

Joseph T Shieh (JT)

Division of Medical Genetics, Department of Pediatrics, Institute for Human Genetics, University of California San Francisco, San Francisco, California.
Institute for Human Genetics and Department of Pediatrics, University of California San Francisco, San Francisco, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH